J.P. Morgan resumes coverage on Stoke Therapeutics with 'overweight'; shares rise

** Shares of U.S. biotechnology firm Stoke Therapeutics STOK.O rise 1.4% to $31.85 in premarket trading

** J.P. Morgan resumes coverage with "overweight" rating, price target $40

** Sees a "high probability of success for zorevunersen’s phase III EMPEROR trial in Dravet on its primary endpoint of seizure reduction"

** Earlier this month, STOK's Q2 revenue fell due to lower collaboration and licensing revenue, and net loss widened

** All 14 brokerages rate STOK "buy" or higher; their median PT is $46 - LSEG-data

** Up to last close, the stock is down 1% YTD